Some investors think billionaire Seth Klarman is the next Warren Buffett. Given that Klarman's $31 billion fund, Baupost Group, has achieved average annual returns of 17% a...
Keep Reading →
October 14 - News
Smart money have been warning about the burst of the biotech bubble for a while now and it looks like they have been right on the money.
Keep Reading →
September 9 - Hedge Funds, News
After compiling and analyzing the most recent 13F filings of hedge funds, we have found that Richard Perry’s Perry Capital and Seth Klarman’s Baupost Group keep around 14% ...
Keep Reading →
June 30 - Hedge Fund Analysis, Hedge Funds, News
The Baupost Group is a Boston-based hedge fund founded and operated by billionaire Seth Klarman.
Keep Reading →
May 22 - Hedge Funds, News
Billionaire Seth Klarman is a notorious investor who despite his uncoventional approaches always managed to achieve high returns.
Keep Reading →
March 15 - Hedge Funds, News
In two recently amended filings David Cohen and Harold Levy's Iridian Asset Management has disclosed further increasing its passive stakes in Theravance Inc (NASDAQ:THRX) to...
Keep Reading →
March 6 - Hedge Funds, News
David Cohen and Harold Levy’s Iridian Asset Management filed several 13G forms with the U.S.
Keep Reading →
January 30 - Hedge Funds, News
On Wednesday, May 14th, Seth Klarman’s Baupost Group, presented its Form 13F Filing for the first quarter of 2014 at the U.S. Securities and Exchange Commission.
Keep Reading →
May 15 - Hedge Funds
Baupost Group, managed by Seth Klarman, in a new 13F filing, reported the holdings from its equity portfolio for the fourth quarter.
Keep Reading →
February 14 - Hedge Funds, News
Relvar Ellipta: Over the past few days, research-based pharmaceutical GlaxoSmithKline plc (ADR) (NYSE:GSK) and biopharmaceutical company Theravance Inc (NASDAQ:THRX)’s Relvar...
Keep Reading →
September 23 - News
GlaxoSmithKline plc (ADR) (NYSE:GSK) and its partner Theravance Inc (NASDAQ:THRX) recently scored a second victory in their quest to treat chronic obstructive pulmonary disease...
Keep Reading →
September 16 - News
Looking for the best-performing sector in this year's big market rally? It may just be the biotech sector, which has erupted with astronomical gains in 2013.
Keep Reading →
September 16 - News
There hasn't been a dull moment for investors of Theravance Inc (NASDAQ:THRX) since the company submitted an NDA for COPD/asthma drug BREO before the Food and Drug Administration...
Keep Reading →
September 12 - News
At the moment, there are many indicators investors can use to analyze stocks. Some of the most under-the-radar are hedge fund and insider trading activity.
Keep Reading →
September 12 - News
Trading of biopharmaceutical company Theravance Inc (NASDAQ:THRX) was halted on Tuesday. A major decision hung in the balance as the U.S.
Keep Reading →
September 11 - News
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Keep Reading →
September 9 - News
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
September 9 - News
In the 21st century investor’s toolkit, there are many gauges shareholders can use to track their holdings.
Keep Reading →
August 30 - News
In the eyes of many investors, hedge funds are seen as overrated, old financial tools of a forgotten age.
Keep Reading →
August 28 - News
In today’s marketplace, there are dozens of gauges shareholders can use to watch stocks. A pair of the most innovative are hedge fund and insider trading movement.
Keep Reading →
August 27 - News
In the financial world, there are many methods shareholders can use to track stocks. A couple of the most innovative are hedge fund and insider trading activity.
Keep Reading →
August 27 - News
In today’s marketplace, there are a multitude of gauges market participants can use to analyze their holdings.
Keep Reading →
August 27 - News
In today’s marketplace, there are a multitude of methods shareholders can use to watch stocks.
Keep Reading →
August 27 - News
In today’s marketplace, there are a multitude of methods shareholders can use to monitor the equity markets.
Keep Reading →
August 25 - News
Today let's look at investing giant Seth Klarman, who founded the Baupost Group hedge fund company back in 1982. Klarman is a successful investor with a lot to teach us.
Keep Reading →
August 23 - Hedge Funds
Chronic obstructive pulmonary disease (COPD) is America’s third leading cause of death.
Keep Reading →
August 5 - News
To most people, cigarettes are often associated with lung cancer.
Keep Reading →
July 30 - News
Over 13 million Americans have it. More than 120,000 of them die every year.
Keep Reading →
July 17 - News
Recently Elan Corporation, plc (ADR) (NYSE:ELN)'s shareholders voted against management's proposal to invest $1 billion in Theravance Inc (NASDAQ:THRX), a deal which a fellow...
Keep Reading →
June 18 - News
In the eyes of most investors, hedge funds are seen as slow, old investment vehicles of yesteryear.
Keep Reading →
June 11 - News
Is Incyte Corporation (NASDAQ:INCY) a buy, sell, or hold? Investors who are in the know are taking an optimistic view.
Keep Reading →
June 3 - News
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
May 20 - News
There's good news and bad news for Americans. The good news is that the age-adjusted death rate in the U.S.
Keep Reading →
May 20 - News
As part of the split, the pharmaceutical company looks poised to turn its current drug-marketing joint venture with London-based GlaxoSmithKline plc (ADR) (NYSE:GSK) into an...
Keep Reading →
May 15 - News
Back towards the end of April 2013, Theravance Inc (NASDAQ:THRX) surprised everyone when it announced plans to split into two separate companies.
Keep Reading →
May 14 - News
With the SPDR S&P Biotech Index up 32% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
May 13 - News
Editor's Note: Related tickers: Wal-Mart Stores, Inc. (NYSE:WMT), Tesco Corporation (USA) (NASDAQ:TESO), Goldman Sachs Group, Inc. (NYSE:GS), Virgin Media Inc.
Keep Reading →
May 13 - News
Infinity Pharmaceuticals Inc. (NASDAQ:INFI) was in 22 hedge funds' portfolio at the end of December. INFI has experienced an increase in enthusiasm from smart money of late.
Keep Reading →
May 9 - News
Investments in biotechnology by the average investor tend to deliver hit or miss returns over time.
Keep Reading →
May 8 - News
The best thing about the stock market is that you can make money in either direction. Historically, stock indexes have tended to trend up over the long term.
Keep Reading →
May 6 - News
Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can'...
Keep Reading →
May 5 - News
One of the nice things about owning biotech companies is the large number of acquisitions in the sector.
Keep Reading →
April 30 - News
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
April 27 - News
Following in the footsteps of Abbott Laboratories (NYSE:ABT) spinning out its drug division into AbbVie Inc (NYSE:ABBV), and Pfizer spinning out its animal health division into...
Keep Reading →
April 26 - News
With the SPDR S&P Biotech Index up 37% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
April 20 - News
Editor's Note: Related tickers: Theravance Inc (NASDAQ:THRX), GlaxoSmithKline plc (NYSE:GSK), Travelzoo Inc. (NASDAQ:TZOO), Arch Coal Inc (NYSE:ACI), Overstock.com, Inc.
Keep Reading →
April 18 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
April 18 - News
According to a 13G filed with the SEC, SAC Capital Advisors, a hedge fund managed by billionaire Steve Cohen, owned 2.4 million shares of Infinity Pharmaceuticals Inc.
Keep Reading →
April 17 - Hedge Funds
Editor's Note: Related tickers: Theravance Inc (NASDAQ:THRX), VIVUS, Inc. (NASDAQ:VVUS), Amgen, Inc.
Keep Reading →
April 15 - News
Theravance Inc (NASDAQ:THRX) has experienced a decrease in support from the world's most elite money managers of late, but insiders on the whole appear bullish.
Keep Reading →
April 15 - News
